CADILA HEALTHCARE LTD. - 532321 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Loss of share certificate26-09-2019
26-09-2019
Cadila Healthcare Ltd - 532321 - Update
Company's API manufacturing facility located at Ankleshwar (Unit 1), Gujarat has received an Establishment Inspection Report (EIR). The USFDA had conducted an inspection at the facility from 22nd to 26th July 2019. The EIR report stated that the classification of the facility is 'No Action Indicated (NAI)'23-09-2019
CADILA HEALTHCARE LTD. - 532321 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Loss of share certificate11-09-2019
CADILA HEALTHCARE LTD. - 532321 - Disclosure Under SEBI Insider Trading Regulations, 2015.
Disclosure under SEBI Insider Trading Regulations, 2015.06-09-2019
CADILA HEALTHCARE LTD. - 532321 - Disclosure Under Insider Trading Regulations, 2015
Disclosure under Insider Trading Regulations, 201504-09-2019
CADILA HEALTHCARE LTD. - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus to launch novel biologic for rabies, TwinrabTM03-09-2019
Cadila Healthcare Ltd - 532321 - Disclosure Under SEBI Insider Trading Regulations
Disclosure under SEBI Insider Trading Regulations31-08-2019
Cadila Healthcare Ltd - 532321 - Shifting Of Registered Office
Shifting of Registered Office30-08-2019
Cadila Healthcare Ltd - 532321 - Disclosure Under Regulation 7(2) Of SEBI PIT Regulations.
Disclosure under Regulation 7(2) of SEBI PIT Regulations.30-08-2019
Zydus Cadila gets USFDA nod to market generic chronic angina drug
Drug firm Zydus Cadila on Wednesday said it has received final approval from the US health regulator to market generic Ranolazine Extended-Release ta21-08-2019